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In the experimental mice infection sustained by Mycobacterium tuberculosis H37Rv, FCE 22250 shows an efficacy 14 times higher than rifampicin and is still therapeutic when administered once every three weeks.
The chemistry and the main biological properties of a new class of 3-azinomethylrifamycins have been described in a previous paper by MARSILI et al.1). One member of this class, 3-(N-piperidinomethylazino)methylrifamycin SV ( Fig. 1) , whose code number is FCE 22250 (compound No. 1 in the earlier paper) has been selected for its outstanding biological characteristics including antibacterial activity and favorable pharmacokinetic properties. Its activity and pharmacokinetics in laboratory animals are reported in this paper.
Materials and Methods
Compounds FCE 22250 and rifampicin were used for the in vitro tests. Both compounds were dissolved in dimethylformamide (DMF) in a concentration of 1,000 Itg/ml and subsequently diluted in 1/15 m phosphate buffer (pH 7.2). For the administration to laboratory animals the compounds were dissolved in phosphate buffer (pH 7.2) plus DMF 5 % (mice and rats) or suspended in aqueous solution of 1 % lauryl sulfate (dogs).
Minimum Inhibitory Concentration (MIC)
The MIC values were determined on clinical and laboratory strains (see Tables 1 and 2 ) according to the following methods: a) Gram-positive and Gram-negative Bacteria: MICs were performed by the serial dilutions technique in Bacto Antibiotic Medium 3 (Difco) supplemented with 1.5 % of Agar (Difco) for aerobic strains and in Bacto FTM (Difco) for the anaerobic strains. The inoculum consisted of about 104 cells per plate or per ml. Incubation was at 37°C for 1~2 days. b) Mycobacterium tuberculosis, M. bovis and M. ulcerans: MICs were determined by the serial dilution technique in Bacto Albumin Dubos Medium (Difco) inoculated with about 108 cells/ml and incubated for 7 days at 37C. c) Other Wycobacteria: MICs were performed on Middlebrook 7H10 Medium (Difco)+OADC plates containing the antibiotics at various concentrations. The surface of the plates was inoculated with the aid of a multipoint inoculator yielding approximately 104 cfu per spot. Incubation was at 37°C for 3~4 days.
In Vivo Therapeutic Activity a) Gram-positive and Gram-negative Bacteria : Groups of 8~10 female CD1 albino mice (Cobs) weighing 20±2 g were infected by intraperitoneal (ip) route with 5 LD50 of the tested strains. The animals were treated by oral (po) or subcutaneous (sc) route (0.1 ml/ 10 g of body weight)
as reported in Table 3 . The number of survivors was recorded over 96 hours and the ED50 was determined according to LITCHFIELD and WILCOYON2). b) M. tuberculosis: Groups of 10~12 mice as described above, were infected by intravenous (iv) route with 3 LD50 of M. tuberculosis H37Rv.
The antibiotics were given by oral route according to various schedules as specified in Table 4 . The number of survivors was recorded over 6 weeks and ED50 was determined as above. Mycobacterium tuberculosis (7) M. tuberculosis SM-EMB-INH Res (4) M. tuberculosis Rif Res (10) M. ulcerans (2) M. marinum (6) M. kansasii (9) M. scrofulaceum (5) M. avium-intracellulare (6) M. chelonei (4) M. fortuitum (10) or orally with 10 mg/kg of antibiotic prepared as described for therapeutic activity; at different intervals 6 animals were sacrificed, plasma was collected and tissues were removed and homogenized in phosphate buffer (pH 7). Individual samples were assayed for antibiotic content on Micrococcus luteus ATCC 9341 by the agar diffusion technique against standard solutions prepared in blank samples of homologous tissues. The limit of detection was 0.1 lig/ml of plasma and 0.2 pg/g of tissues. b) Rats: Groups of 3~9 CD albino rats (Cobs) weighing 250±20 g were treated intravenously or orally with 10 mg/kg of an antibiotic; at various times one group was sacrificed and plasma and tissues were assayed for antibiotic content as described above. c) Dogs: 3 Animals weighing about 10 kg were treated by oral route with 30 mg/kg of FCE 22250. At various times after the administration, plasma samples were collected and the antibiotic content in plasma was determined by microbiological assay as previously described.
Results

In Vitro and In Vivo Activity
The in vitro activity against Gram-positive and Gram-negative bacteria is reported in Table 1 .
Against the majority of the tested bacteria both FCE 22250 and rifampicin have similar activity.
Only against Neisseria, Haemophilus and anaerobes FCE 22250 is 3~10 times less active than rifampicin.
In Table 2 In mice the plasma half-life can be estimated at 19 hours following either po or iv administration.
The plasma levels following gavage of 10 mg/kg reach maximum (7 tag/ml) at about 7 hours after dosing.
In rats the half-life is about 45 hours following iv injection, while following po administration the plasma levels remain almost unchanged until 25 hours after dosing when the concentrations decline with Until 72 hours the levels decrease slowly and after that time the rate of elimination increases; in this phase the half-life can be estimated as 24 hours. Increasing in the rate of elimination is observed in rats and dogs respectively at 36 and 72 hours following oral administration; metabolic activation can be hypothesized.
The bioavailability following oral administration has been also determined; the ratio of plasma AUCs (0-48 hours) following oral and intravenous treatment is 82% in mice and 87% in rats.
The tissue levels of FCE 22250 and rifampicin in mice and rats are reported in Figs. 6 and 7. The penetration of FCE 22250 is good in both species; the lung, kidney and plasma concentrations are similar at almost all the times considered while higher levels are reached in liver. The ratio liver/ plasma ranges from 4.9 (7 hours) to 12.7 (72 hours) in mice and from 2.5 (7 hours) to 15.4 (72 hours) in rats. At the earlier times the levels and the pattern of distribution of rifampicin are similar to FCE 22250, but after 24 hours the concentrations are lower and similar to those observed with FCE 22250 after 72 hours. of rifampicin even though their intrinsic in vitro activities are similar. This high in vivo efficacy is very probably due to the more prolonged blood and tissue levels observed than those of rifampicin. The activity against atypical mycobacteria is also of some interest, especially against M. fortuitunt, but more investigations are needed to determine if the observed inhibiting concentrations are of therapeutic value. The in vitro activity of FCE 22250 against Gram-positive and Gram-negative bacteria is similar to that of rifampicin but its ability to cure mice septicemias is lower than expected.
For many years after the development of rifampicin, no antibiotic of this class with clinical potential has been presented, but recently two new rifamycins, LM 427" and DL 4735), with remarkable activity have been synthesized and are now in clinical trials. In comparison with these compounds, FCE 22250 strongly differs from LM 427, which is a drug with an outstanding activity on atypical mycobacteria and many rifampicin-resistant M. tuberculosise'", but can be compared to DL 473 which is characterized by a long half-life and a spectrum on mycobacteria very similar to that of rifampicin5).
Studies aimed at determining the pharmacokinetics of FCE 22250 in humans are under way. If the data are in agreement with those observed in animals, this compound will be an excellent candidate for tubercular and leprosy therapy.
